RS59399B1 - Antitela protiv cd38 za lečenje multiplog mijeloma - Google Patents

Antitela protiv cd38 za lečenje multiplog mijeloma

Info

Publication number
RS59399B1
RS59399B1 RSP20191301A RS59399B1 RS 59399 B1 RS59399 B1 RS 59399B1 RS P20191301 A RSP20191301 A RS P20191301A RS 59399 B1 RS59399 B1 RS 59399B1
Authority
RS
Serbia
Prior art keywords
formula
compound
process according
och3
aryl
Prior art date
Application number
Other languages
English (en)
Inventor
Weers Michel De
Yvo Graus
Judith Oprins
Paul Parren
De Winkel Jan Van
Vugt Martine Van
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59399(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab As filed Critical Genmab As
Publication of RS59399B1 publication Critical patent/RS59399B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99002—Monosialoganglioside sialyltransferase (2.4.99.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91148—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)

Description

POSTUPAK I INTERMEDIJARI ZA POBIJANJE INHIBITORA
5- LIPOKSIGENAZE
Osnova pronalaska
Ovaj pronalazak se odnosi na postupak i intermedijare za dobijanje inhibitora 5-lipoksigenaze. Inhibitori 5-lipoksigenaze koji se dobijaju shodno ovom pronalasku izloženi su u SAD Patentnoj prijavi serijski br. 09/020,0140 koja je nastavak prijave br. 08/809,901 podnete 13. Juna 1997, od koje se sada odustalo. Ova (pending) prijava koja je pod haslovom inhibitori 5-lipoksigenaze je ovde uključena u svojoj celosti kao referenca.
Inhibitori 5-lipbksigenaze koji se dobijaju shodno ovom pronalasku su selektivni inhibitori aktivnosti enzima lipoksigenaze i korisni su u tretmanu ili ublažavanju inflamatornih bolesti, alergije i kardiovaskularnih bolesti kod sisara.
Kratak sadržaj pronalaska
Ovaj pronalazak se odnosi na postupak za dobijanje jedinjenja Formule
Pri čemu A je CVCsalkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Csalkil ili benzil, a koji obuhvata reagovanje jedinjenja Formule
Pri čemu A je C^Csalkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrC3alkil ili benzil, sa sulfo kiselinom u C^Csalkil alkoholu; i taloženjem jedinjenja Formule I dodavanjem nekog organskog rastvarača koji je manje polaran od alkohola.
Kiselina je metansulfo kiselina a organski rastvarač je diizopropil eter ili etil acetat.
U narednom aspektu ovog pronalaska jedinjenje Formule II se dobija reakcijom jedinjenja Formule
Pri čemu A je CrC6alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrCaalkil ili benzil, sa hidroksidom u nekom alkoholnom rastvaraču.
Hidroksid je kalijum hidroksid, a alakohol je tercijerni butil alkohol.
U narednom aspektu ovog pronalaska jedinjenje Formule III se dobija reakcijom jedinjenja Formule
Pri čemu X je Cl, Br ili I sa viškom 4-amin-tiofenol sa bazom u nekom inertnom rastvaraču da bi se dobilo jedinjenje Formule
I daljim tretiranjem jedinjenja Formule VII acilacijom sa nekim kiselim halidom ili anhidridom.
Drugi još poželjniji način dobijanja jedinjenja Formule VI je reakcijom jedinjenja Formule VIII
Pri čemu X je Cl, Br ili I sa viškom 4-amid-tiofenol sa bazom u nekom inertnom rastvaraču.
Pri čemu A je C^Cealkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Caalkil ili benzil, sa organskom ili mineralnom kiselinom.
Kiselina je sirćetna, sumporna, mravlja ili p-toluensulfo kiselina. Preferirana kiselina je mravlja.
U narednom aspektu ovog pronalaska jedinjenje Formule IV se dobija reakcijom jedinjenja Formule
Pri čemu A je CrCsalkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrCaalkil ili benzil, i pri čemu X je Cl, Br, I, ili OCH3sa viškom amino acetaldehid acetala.
Amino acetalaldehid acetal je aminoacetalaldehid dimetilacetal ili aminoacetalaldehid deietil acetal.
U narednom aspektu ovog pronalaska jedinjenje Formule V, pri čemu X je Cl, Br ili I je dobijeno reakcijom jedinjenja Formule
Pri čemu A je C^Csalkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Csalkil ili benzil, sa fosfornim pentahalidom u nekom inertnom rastvaraču. Jedinjenje Formule V može takodje da bude dobijeno reakcijom jedinjenja Formule VI sa(CH3)30<*>BF4da formira intermedijar gde x je OCH3.
Pentahalid je fosforni pentahlorid, fosforni pentajodid ili fosforni pentabromid, a rastvarač je toluen. Preferirani A je CH3.
U narednom aspektu ovog pronalaska jedinjenje Formule VI, se dobija reakcijom jedinjenja Formule 4-amid-tiofenol je 4-acetamid-tiofenol. Rastvarač je NMP ili DMSO.
Baza je natrijum karbonat / cezijum karbonat.
U narednom aspektu ovog pronalaska jedinjenje Formule VIII, može biti dobijeno reakcijom jedinjenja Formule
Pri čemu X je Br, Cl ili I sa bis-2-hloretil etrom, nekom alkalnom bazom i faznim transfer katalizatorom u nekom inertnom rastvaraču.
Fazni transfer katalizator je tetrabutil amonijum hidrogen sulfat. Baza je natrijum hidroksid.
Inertni rastvarač je smeša tetrahidrofurana i vode.
Pronalazak se takodje odnosi na novo jedinjenje Formule
Pronalazak se takodje odnosi na novo jedinjenje Formule
Pri čemu A je CrC6alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrC3alkil ili benzil.
Pronalazak se takodje odnosi na novo jedinjenje Formule
Pri čemu A je C^C^IkN, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrC3alkil ili benzil i pri čemu X je I, Br, Cl ili OCH3.
Pronalazak se takodje odnosi na novo jedinjenje Formule
Pri čemu A je CrC6alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C1-C3alkil ili benzil i pri čemu R je C^Cgalkil.
Pronalazak se takodje odnosi na novo jedinjenje Formule
Pri čemu A je CVC^alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrCgalkil ili benzil.
Preferirano jedinjenje je
Ova nova jedinjenja se koriste u dobijanju inhibitora 5-lipoksigenaze i njihovih farmaceutskih sastava korisnih u tretmanu ili olakšavanju inflamatornih bolesti, alergije i kardiovaskularnih bolesti kod sisara.
Detaljan opis pronalaska
Nov^ postupak sinteze je prikazan niže u Shemi reakcije I
3-bromfenil acetonitril u tetrahidrofuranu je tretiran sa razvodnjenom NaOH, tetra butil amonijum hidrogen sulfatom i bis-2-hlor-etil etrom da bi se dobio aril bromid jedinjenje Formule VIII.
Arilbromid jedinjenje VIII je tretiran bilo sa 4-amintiofenol da bi se dobilo anilin jedinjenje VII čemu sledi acilacija ili sa 4-amidtiofenil da bi se dobilo amid jedinjenje VI. Imidazol funkcija je inkorporirana transformacijom amidogrupe formule VI grejanjem jedinjenja VI sa fosfornim pentahalidom da bi se dobilo jedinjenje V koje je tretirano sa aminacetaldehid alkil acetalom dajući amidin jedinjenje IV. Amidin jedinjenje IV egzistira kao smeša tautomera koji nisu izolovani i koji su odmah izloženi ciklizaciji izazvanoj kiselinom da bi se dobilo imidazol jedinjenje III. Naknadna hidroliza nitril funkcije imidazol jedinjenja III daje inhibitor 5-lipoksigenaze jedinjenja II. Preferirani slani oblik je pronadjena tretiranjem jedinjenja II sa metansulfo kiselinom da bi se dobilo jedinjenje I.
Novi proces iz ovog pronalaska eliminiše prethodne dve skupe reakcije paladijum (O) kuplovanja predstavljajući sulfidno vezivanje za molekul kao što je opisano u. SAD patentnoj prijavi 09/020,0140. koja je ovde u svojoj celosti uključena kao" referenca. Pored toga, gore navedeni i poželjni atom sumpora je prethodno uveden posredstvom TIPS-tiol reagensa (TIPS je triizopropil silil), koji je dobijen iz toksičnog hidrogen sulfida i skupog TIPS-hlorida.
Jedinjenje I gde A je CH3je preferirana slana forma inhibitora 5-lipoksigenaze korisnih u tretmanu ili olakšavanju inflamatornih bolesti, alergije i kardiovaskularnih bolesti kod sisara. Jedinjenje I je posebno korisno u tretmanu ili olakšavanju inflamatornih bolesti.
Ovi korisni inhibitori 5-lipoksigenaze mogu da budu davani u širokom nizu obliku doza.
Za tretman različitih gore opisanih stanja jedinjenja i njihove farmaceutski prihvatljive soli mogu da budu davane čoveku bilo sama, ili - što je poželjnije- u kombinaciji sa farmaceutski prihvatljivim nosiocima ili ražblaživačima u farmaceutskom sastavu shodno standardnoj farmaceutskoj praksi. Jedinjenja mogu da budu davana na konvencionalan način oralno ili parenteralno. -'--.->
Kada se jedinjenja daju čoveku radi prevencije ili lečenja neke inflamatorne bolesti, raspon oralne doze bi bio od oko 0.1 do 10mg/kg telesne težine pacijenta koji se tretira, dnevno, poželjno od oko 0.1 do 4mg/kg dnevno u jednoj ili podeljenim dozama. Ukoliko je poželjno parenteralno davanje, tada bi efektivna doza bila od oko 0.05 do 5mg/kg telesne težine pacijenta koji se tretira, dnevno. U nekim slučajevima može da bude neophodno da se primene doze izvan tih limita pošto doziranje nezaobilazno varira u zavisnosti od starosti, težine i individualnog reagovanja pacijenata, kao i od oštrine simptoma kod pacijenta, te od potencije pojedinačnog jedinjenja koje se daje.
Za oralno davanje, jedinjenja iz ovog pronalaska i njihove farmaceutski prihvatljive soli mogu, primera radi, da budu davana u obliku tableta, praškova, pilula, sirupa ili kapsula, ili kao razvodnjeni rastvor ili suspenzija. U slučaju tableta za oralnu primenu, medju obično korišćenim nosiocima su laktoza i kukuruzni škrob. Dalje,, obično se dodaju i lubrifikacioni agensi, kao što je magnezijum stearal. Kod kapsula -su karisni razredjivači laktoza ili osušeni kukuruzni škrob. Kada su potrebne razvodnjene suspenzije za oralnu primenu, tada je aktivni sastojak pomešan sa agensima emulzifikacije i suspenzije. Ukoliko se želi, mogu se dodati odredjeni agensi ukusa i/ili zaskadjenja. Za intramuskularno, intraperitonealno, podkožno i intravenozno korišćenje obično se pripreme sterilni rastvori aktivnog sastojka, a pH rastvora treba da bude prilagodjen i puferiran. Za intravenozno korišćenje treba da bude kontrolisana totalna koncentracija rastvora kako bi bio izotonski.
Pored toga, posebno za tretman astme, jedinjenja Formule I iz ovog pronalaska mogu biti data pacijentu i inhalacijom. U tom cilju mogu biti davana kao sprej ili kapljičasto shodno standarnoj praksi.
Ovaj pronalazak je islutrovan primerima datim u nastavku, aili nije ograničen njihovim detaljima.
Primer I
4-(3-brom-fenil)-tetrahidro-piran-4-karbonitril
3-bromfenilacetonitril (51 g) u THF (300ml_) je tretiran sa 14% razvodnjenom NaOH (470ml_), tetrabutilamonijum hidrogen sulfatu (9g) i kapanjem dodavanim bis-2-hloretiletrom (32ml_). Reakciona smeša je pod refluksom grejana 4 sata i zatim ohladjena. Smeša je razblažena sa EtOAc (400mL), isprana sa 5% HCI (200mL), vodom (200mL) i zasićenim NaHC03. Posle sušenja preko Mg2S04odstranjen je rastvarač da bi se dobio sirovi CP-399,554 kao voskasta čvrsta supstanca (75,4g). Masa je razmuljena u smešu 1:1 izopropil etra i heksana (100ml_) i dobijeno je 4-(3-brom-fenil)-tetrahidro-piran-4-karbonitril (55,3g, prinos 85%). Primer II 4-[3-(4-amin-fenil-sulfanil)-fenil]-tetrahidro-piran-4-karbonitril 4-(3-brom-fenil)-tetrahidro-piran-4-karbonitril (133.4g), Na2C03(363.6g), CS2C03(223.1 g) i amintiofenol (62.8g) su grejani 24 sata u N-metil-pirolidinonu (2.3L) na 130°C. Dodato je još amintiofenola (35.6g) i grejanje je nastavljeno još 8 sati. Smeša je ohladjena do sobne temperature, sipana na ledenu vodu (6.8L) i filtrirana je. Proizvod je suspendovan u vodi (2.5L), ponovo filtriran i ispran vodom (1.5L). Zatim je proizvod razmuljen u EtOH (0.5L), filtriran i osušen na 40°C / 20mbar dajući 4-[3-(4-amin-fenil-sulfanil)-fenil]-tetrahidro-piran-4-karbonitril (134.3g, 86%). Primer III N-{4-[3-(4-cijan-tetrahidro-piran-4-il)-fenil-sulfanil]-fenil}acetamid 4-(3-brom-fenil)-tetrahidro-piran-4-karbonitril (1.33g), je mešan sa Na2C03(1.59g), CS2C03(0.651 g) i 4-acetamidtiofenol (1g) u N-metil-pirolidinonu (15mL). Reakciona smeša je grejana preko noći na 130°C. Posle hladjenja, smeša je sipana na ledenu vodu. Proizvod se nataložio kao čvrsta masa i prikupljen je usisavanjem uz filtriranje. Čvrsta masa je rekristalizovana iz smeše EtOAc i heksana dajući N-{4-[3-(4-cijan-tetrahidro-piran-4-il)-fenil-sulfanil]-fenil}acetamid (1.4g, prinos 80%). Primeri II i III - kombinovano N-{4-[3-(4-cijan-tetrahidro-piran-4-il)-fenil-sulfanil]-fenil}acetamid
4-[3-(4-amin-fenil-sulfanil)-fenil]-tetrahidro-piran-karbonitril (93.57g) i Et3N (53.1 mL) su rastvoreni u EtOAc (1.23L) i grejani na 50-60°C. U ovaj rastvor je tokom 30 minuta dodavan acetilhlorid (27.7ml_) u EtOAc (73ml_).
Dobijena suspenzija je filtrirana, a filterski kolač je ispran sa EtOAc (3 x 150mL). Kombinovani EtOAc rastvori su isprani vodom (0.5L), poluzasićenim razvodnjenim Na2C03(2 x 0.5L), vodom (0.5L) i zasićenim razvodnjenim NaCI (0.25L). Organski sastojci-su osušeni sa Na2S04i ispareni na 40°C. Sirovi proizvod je rekristalizovan iz refluksovanog EtOH (0.52L), posle hladjenja, filtriranja i sušenja na 40°C / 20mbara dao je N-{4-[3-(4-cijan-tetrahidro-piran-4-il)-fenil-sulfanil]-fenil}acetamid (55.27g, prinos 52%).
Primer IV
4-{3-[4-(2-metil-imidazol-1-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-karbonitril
N-4-[3-(4-amin-fenil-sulfanil)-fenil]-tetrahidro-piran-karbonitril (49.77g) je rastvoren u toluenu (545mL) i grejan do 60°C pod azeotropnim uslovima. Iz ovog rastvora je azeotropirano 20mL rastvarača da bi se odstranila preostala voda. U rastvor je u više porcija dodat je PCI5(35g.). Posle jednosatnog mešanja na 60°C rastvarač je destilovan. Ostatak je ohladjen do 10°C i dodata je smeša Et3N (19.8mL) i aminacetaldehid dimetilacetala (15.2ml_) u EtOAc (500mL). Dobijena suspenzija je mešana 30 minuta na 10°C , a zatim je dodato još EtOAC (150mL). Smeša je isprana vodom (360mL) a potom zasićenim razvodnjenim NaCI (150ml_). Organski sastojci su osušeni sa Na2S04(52g) i ispareni na 50°G.'-'Ostatak je rastvoren u mravljoj kiselini (250mL) i grejan 1 sat do refluksa. Reakciona smeša je koncentrovana na 50°C/100mbar do stanja ulja. Ulje je rastvoreno u 10% razvodnjenoj limunskoj kiselini (400mL) i EtOAC (200ml_). Vodeni sloj je ekstrahovan sa EtOAC (200ml_). PH vodenog sloja je podešen na 9 - 10 sa polu-zasićenim rastvorom K2C03(175ml_), a rastvor je ekstrahovan sa EtOAC (200mL). Ekstrakt je osušen sa Na2S04(48g) i isparen na 50°C / 100mbara dajući posle filtriranja kroz silika podlogu koristeći CH2CI2/ MeOH 10% kao razredjivač, 4-{3-[4-(2-metil-imidazol-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-karbonitril (27.6g, ukupan prinos 55%).
Primer V
4-{3-[4-(2-metil-imidazol-1-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-amid karboksilne kiseline
4-{3-[4-(2-metil-imidazol-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-karbonitril (27.35g,) je rastvoren u t-BuOH (280mL) na 50°C. U rastvor je dodat KOH (12.28g) i smeša je mešana preko noći. Suspenzija je ohladjena do sobne temperature i dodata je voda (180mL). Dobijena suspenzija je filtrirana i filterski kolač je osušen na 50°C dajući 4-{3-[4-(2-metil-imidazol-1-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-amid karboksilne kiseline (17.52g, prinos 55%). Primer VI 4-{3-[4-(2-metil-imidazol-1-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-metil sulfonat amid karboksilne kiseline
4-{3-[4-(2-metil-imidazol-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-amid karboksilne kiseline (5.05g,) je suspendovan u MeOH (39ml_) na sobnoj temperaturi. U suspenziju je dodavana metansulfo kiselina kap po kap dok se
sav materijal nije rastvorio. Dobijeni rastvor je filtrran, a filtrat je ispran sa MeOH (20mL). Kombinovani MeOH rastvori su tretirani sa diizopropiletrom (280ml_) na sobnoj temperaturi., Posle mešanja tokom noći formirali su se kristali koji su prikupljeni filtriranjem i osušeni su na 40°C / 19mbar dajući 4-{ 3-[4-(2-metil-imidazol-1-il)-fenil-sulfanil]-fenil}-tetrahidro-piran-4-metil sulfonat amid karboksilne kiseline (4.85g, prinos 77%).

Claims (30)

1. Postupak za dobijanje jedinjenja Formule Pri čemu A je CrC6alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, ^^alkil ili benzil a koji obuhvata reagovanje jedinjenja Formule Pri čemu A je CrCsalkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrCsalkil ili benzil, sa sulfo kiselinom u C^C^IkN alkoholu; i b taloženjem jedinjenja Formule I dodavanjem nekog organskog rastvarača koji je manje polaran od alkohola.
2. Postupak u skladu sa Zahtevom 1 gde je kiselina metansulfo kiselina.
3. Postupak u skladu sa Zahtevom 1 gde je organski rastvarač diizopropil eter ili etil acetat.
4. Postupak iz Zahteva 1 gde se navedeno jedinjenje Formule II dobija reakcijom jedinjenja Formule Pri čemu A je C^Cealkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Caalkil ili benzil, sa hidroksidom u nekom alkoholnom rastvaraču. -
5. Postupak u skladu sa Zahtevom 4 gde hidroksid je kalijum hidroksid.
6. Postupak u skladu sa Zahtevom 4 gde je alakohol tercijerni butil alkohol.
7. Postupak u skladu sa Zahtevom 4 gde se navedeno jedinjenje Formule III dobija reakcijom jedinjenja Formule Pri čemu A je CrC6alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3) C^Caalkil ili benzil, sa organskom ili mineralnom kiselinom.
8. Postupak u skladu sa Zahtevom 7 gde je kiselina sirćetna, sumporna, mravlja ili p-toluensulfo kiselina.
9. Postupak u skladu sa Zahtevom 8 gde je preferirana kiselina mravlja kiselina.
10. Postupak u skladu sa Zahtevom 7 gde se navedeno jedinjenje Formule IV dobija reakcijom jedinjenja Formule Pri čemu A je C^Cealkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Cgalkil ili benzil, i pri čemu X je Cl, Br, I, ili OCH3sa viškom amino acetaldehid acetala.
11. Postupak u skladu sa Zahtevom 10 gde amin acetalaldehid acetal je aminacetalaldehid dimetilacetal ili aminoacetalaldehid deietil acetal.
12. Postupak u skladu sa Zahtevom 10 gde se navedeno jedinjenje Formule V, pri čemu X je Cl, Br ili I dobija reakcijom jedinjenja Formule Pri čemu A je CrCealkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Csalkil ili benzil, sa fosfornim pentahalidom u nekom inertnom rastvaraču, ili gde X je OCH3u Formuli V sa(CH3)30<*>BF4da formira intermedijar.
13. Postupak u skladu sa Zahtevom 12 gde pentahalid je fosforni pentahlorid, fosforni pentajodid ili fosforni pentabromid i rastvarač je toluen.
14. Postupak u skladu sa Zahtevom 12 gde se navedeno jedinjenje Formule VI dobija reakcijom jedinjenja Formule Pri čemu X je Cl, Br ili I sa viškom 4-amin-tiofenol sa bazom u nekom inertnom rastvaraču dajući jedinjenje Formule<r> I daljim tretiranjem jedinjenja Formule VII acilacijom sa nekim kiselim halidom ili anhidridom.
15. Postupak u skladu sa Zahtevom 14 gde je agent acilacije acetil hlorid.
16. Postupak u skladu sa Zahtevom 12 gde se navedeno jedinjenje VI dobija reakcijom jedinjenja Formule VIII Pri čemu X je Cl, Br ili I sa viškom 4-amid-tiofenol sa bazom u nekom inertnom rastvaraču.
17. Postupak u skladu sa Zahtevom 17 gde 4-amid-tiofenol je 4-acetamid-tiofenol.
18. Postupak u skladu sa Zahtevom 16 gde je baza NMP ili DMSO.
19. Postupak u skladu sa Zahtevom 16 gde je baza natrijum karbonat / cezijum karbonat.
20. Postupak u skladu sa Zahtevom 14 gde je je baza natrijum karbonat / cezijum karbonat.
21. Postupak u skladu sa Zahtevom 14 gde je navedeni rastvarač DMSO ili NMP.
22. Postupak u skladu sa Zahtevom 16 gde jedinjenje Formule VIII može biti dobijeno reakcijom jedinjenja Formule Pri čemu X je Br, Cl ili I sa bis-2-hloretil etrom, nekom alkalnom bazom i faznim transfer katalizatorom u nekom inertnom rastvaraču.
23. Postupak u skladu sa Zahtevom 22 gde je inertni rastvarač smeša tetrahidrofurana i vode, baza je natrijum hidroksid i fazni transfer katalizator je tetrabutil amonijum hidrogen sulfat.
24. Jedinjenje Formule ' '■'
25. Jedinjenje Formule Pri čemu A je (VCealkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Caalkil ili benzil.
26. Jedinjenje Formuler Pri čemu A je Ci-C6alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, C^Caalkil ili benzil i pri čemu X je I, Br, Cl ili OCH3.
27. Jedinjenje Formule Pri čemu A je CrCgalkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3>C^Caalkil ili benzil i pri čemu Ft je C^Csalkil.
28. Jedinjenje Formule • Pri čemu A je CrC6alkil, aril, koji je mono ili disupstituiran sa F, Cl, Br, OCH3, CrC<g>alkil "ili benzil.
29. Jedinjenje Formule
30. Jedinjenje Formule gde X je Br, ili Cl.
RSP20191301 2005-03-23 2006-03-23 Antitela protiv cd38 za lečenje multiplog mijeloma RS59399B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US69616305P 2005-07-01 2005-07-01
US72856105P 2005-10-20 2005-10-20
EP17200442.6A EP3312196B1 (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
RS59399B1 true RS59399B1 (sr) 2019-11-29

Family

ID=36617365

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP20191301 RS59399B1 (sr) 2005-03-23 2006-03-23 Antitela protiv cd38 za lečenje multiplog mijeloma

Country Status (27)

Country Link
US (5) US7829673B2 (sr)
EP (6) EP1866338B1 (sr)
JP (12) JP5225069B2 (sr)
KR (1) KR101433381B1 (sr)
CN (4) CN101218256B (sr)
AU (1) AU2006226733C9 (sr)
BR (1) BRPI0608927B1 (sr)
CA (1) CA2602375C (sr)
CY (3) CY1118369T1 (sr)
DK (1) DK2567976T3 (sr)
EA (2) EA015584B1 (sr)
ES (1) ES2716874T3 (sr)
FR (1) FR18C1003I2 (sr)
HR (2) HRP20161766T1 (sr)
IL (8) IL185751A (sr)
LT (1) LTC2567976I2 (sr)
LU (1) LUC00053I9 (sr)
ME (1) ME03528B (sr)
MX (1) MX2007011064A (sr)
NL (1) NL300915I2 (sr)
NZ (2) NZ586780A (sr)
PL (1) PL2567976T3 (sr)
RS (1) RS59399B1 (sr)
SG (1) SG10201912554TA (sr)
SI (1) SI2567976T1 (sr)
WO (1) WO2006099875A1 (sr)
ZA (1) ZA200709003B (sr)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071096B2 (en) 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
AU2006323415A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
CA2656620C (en) 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
US20090029904A1 (en) * 2006-07-21 2009-01-29 Sean Oldham Compositions and methods for treatment of insulin-resistance diseases
US20080317745A1 (en) * 2006-09-15 2008-12-25 Boruchov Adam M Methods of diagnosing, treating, or preventing plasma cell disorders
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US20100041874A1 (en) * 2006-10-03 2010-02-18 Genmab A/S High throughput methods for characterization of antibodies
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2013209322A1 (en) * 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
US8143014B2 (en) * 2007-10-02 2012-03-27 Mayo Foundation For Medical Education And Research CD38 and obesity
WO2009080831A1 (en) 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
WO2009080832A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
CN101965366B (zh) 2007-12-26 2016-04-27 生物测试股份公司 靶向cd138的免疫缀合物及其应用
RU2010138612A (ru) 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
GB0808350D0 (en) * 2008-05-09 2008-06-18 Airbus Uk Ltd Self-cleaning surfaces
US20110076723A1 (en) * 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
CA2761120A1 (en) * 2009-05-06 2010-11-11 Biotest Ag Uses of immunoconjugates targeting cd138
AU2013201618B2 (en) * 2009-05-06 2016-06-02 Biotest Ag Uses of immunoconjugates targeting CD138
WO2011047228A1 (en) 2009-10-16 2011-04-21 Cornell University Measuring subcellular concentrations in vivo
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
DK2621531T3 (en) 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013075740A1 (en) * 2011-11-23 2013-05-30 Sanofi Antibody purification method
KR20140100571A (ko) 2011-12-08 2014-08-14 바이오테스트 아게 Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP2861622A4 (en) 2012-06-15 2016-06-01 Sinomab Bioscience Ltd Anti-idiotypic anti-CD22 antibodies and uses thereof
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
MX368288B (es) 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
JP6374392B2 (ja) * 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
DK2914302T3 (en) 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
EP3666795A1 (en) * 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3301115B1 (en) 2013-05-06 2021-11-10 Sanofi Continuous multistep process for purifying antibodies
EP3021866A4 (en) * 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Medical uses of cd38 agonists
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
JP2017506640A (ja) * 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2809729T3 (es) * 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
JP6935195B2 (ja) * 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
EP3154581B1 (en) 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
SI3157561T1 (sl) * 2014-06-17 2020-08-31 Medlmmune Limited Izboljšana protitelesa alfa-V beta-8
KR20170032406A (ko) 2014-07-15 2017-03-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 조작된 세포
JP6132074B2 (ja) * 2014-08-22 2017-05-24 株式会社村田製作所 触覚提示装置
PH12017500442B1 (en) * 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CN107406506A (zh) * 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
US9951144B2 (en) * 2015-04-08 2018-04-24 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
HUE054271T2 (hu) 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
DK3303396T5 (da) * 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
EP3303373B1 (en) * 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
IL256242B2 (en) * 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
EA037548B1 (ru) * 2015-06-24 2021-04-12 Янссен Байотек, Инк. Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HK1255161A1 (zh) 2015-07-15 2019-08-09 Juno Therapeutics, Inc. 用於过继性细胞治疗的工程细胞
WO2017025323A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2017149122A1 (en) * 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
PT3433273T (pt) * 2016-03-25 2022-02-21 Biomunex Pharmaceuticals Moléculas de ligação a cd38 e pd-l1
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
MA45674A (fr) * 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
WO2018015498A1 (en) 2016-07-20 2018-01-25 Hybrigenics Sa Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
EP3330712A1 (en) * 2016-12-01 2018-06-06 imusyn GmbH & Co. KG Analysis of anti-erythrocyte antibody in the presence of antibody directed against a surface-bound erythrocyte antigen
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
WO2018104562A1 (en) 2016-12-09 2018-06-14 Onkimmune Limited Engineered natural killer cells and uses thereof
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN110997722B (zh) * 2017-06-08 2023-09-26 黑带医疗有限公司 Cd38调节抗体
JP7679196B2 (ja) 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８調節抗体
BR112019027133B8 (pt) 2017-06-20 2022-08-09 Inst Curie Uso de uma célula imune modificada deficiente para suv39h1
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR102770110B1 (ko) 2017-08-16 2025-02-20 블랙 벨트 테라퓨틱스 리미티드 Cd38 항체
CA3073085A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 modulating antibody
EP3681908A1 (en) 2017-09-13 2020-07-22 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
KR20200058540A (ko) * 2017-10-02 2020-05-27 비스테라, 인크. Cd138에 대한 항체 분자 및 이의 용도
BR112020007002A2 (pt) * 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
EP3704229B1 (en) 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Process for producing a t cell composition
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3080109A1 (en) 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
CN107936110B (zh) * 2017-11-07 2021-06-22 潍坊医学院 突变基因Nasp在狼疮性模型小鼠自身免疫病发病中的作用及机制
EP3720882A4 (en) 2017-12-05 2021-10-27 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center T-CELLS WITH TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND THEIR USE
EP3720883B1 (en) 2017-12-05 2023-04-19 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof
US12161670B2 (en) 2017-12-08 2024-12-10 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2019235626A1 (en) * 2018-03-13 2020-10-08 Pfizer Inc. Combination of CD47 blockade therapy and a CD38 antibody
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
KR20250117714A (ko) * 2018-03-28 2025-08-05 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투약
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
UA130542C2 (uk) 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
EP3833685A4 (en) * 2018-07-08 2022-08-17 Specifica Inc. ANTIBODY LIBRARIES WITH FEATURES FOR MAXIMIZED ANTIBODY DEVELOPMENT
US20200017600A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
CN112805378A (zh) 2018-08-09 2021-05-14 朱诺治疗学股份有限公司 用于评估整合核酸的方法
AU2019338999A1 (en) * 2018-09-11 2021-03-18 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
KR20210077725A (ko) 2018-10-17 2021-06-25 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 투여를 제공하는 방법
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
EP3873937A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
EA202191352A1 (ru) 2018-11-13 2021-08-11 Янссен Байотек, Инк. Контроль содержания микроэлементов-металлов во время продукции антител к cd38
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
JP7699542B2 (ja) 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
KR20210104736A (ko) 2018-12-14 2021-08-25 모르포시스 아게 항체 제형
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
GB201900530D0 (en) * 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
JP2022520572A (ja) 2019-02-12 2022-03-31 プロシーナ バイオサイエンシーズ リミテッド 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
WO2020168554A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 改造的Fc片段，包含其的抗体及其应用
WO2020176748A1 (en) 2019-02-27 2020-09-03 Genentech, Inc. Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
EP4582446A3 (en) 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis
JP7687956B2 (ja) 2019-03-15 2025-06-03 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
CA3134612A1 (en) * 2019-03-29 2020-10-08 Sorrento Therapeutics, Inc. Engineered variant antibodies that bind cd38
WO2020212914A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CA3136742A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
EP3980064A1 (en) 2019-06-10 2022-04-13 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
MY210065A (en) * 2019-06-17 2025-08-25 Visterra Inc Humanized antibody molecules to cd138 and uses thereof
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
EP3999540A1 (en) 2019-07-16 2022-05-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Antibodies having specificity for cd38 and uses thereof
BR112022001148A2 (pt) 2019-07-23 2022-03-15 Inst Nat Sante Rech Med Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
KR20220092580A (ko) 2019-11-06 2022-07-01 제넨테크, 인크. 혈액암의 치료를 위한 진단과 치료 방법
IL293563A (en) 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration
CN115023441A (zh) 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
AU2020412805A1 (en) * 2019-12-26 2022-07-14 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent
IL294557A (en) 2020-01-07 2022-09-01 Univ Texas Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
JP6853392B2 (ja) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US20230272105A1 (en) 2020-01-16 2023-08-31 Genmab A/S Formulations of cd38 antibodies and uses thereof
JP7777533B2 (ja) 2020-01-29 2025-11-28 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用
CN115362270A (zh) 2020-01-29 2022-11-18 得克萨斯州大学系统董事会 Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途
JP2023518000A (ja) * 2020-03-13 2023-04-27 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク Ｒｏｒ２をターゲティングする、親和性成熟ヒト化結合性ドメイン
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
JP2023106636A (ja) * 2020-05-22 2023-08-02 国立研究開発法人医薬基盤・健康・栄養研究所 ヒト抗破傷風毒素抗体
US20230312742A1 (en) 2020-06-17 2023-10-05 Y-Mabs Therapeutics, Inc. CD38 antibodies for the treatment of human diseases
CN116670285A (zh) * 2020-06-23 2023-08-29 江苏康缘药业股份有限公司 抗cd38抗体及其用途
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
JP2023531531A (ja) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
EP4188395A1 (en) 2020-07-30 2023-06-07 Institut Curie Immune cells defective for socs1
CN114075283A (zh) 2020-08-12 2022-02-22 三生国健药业（上海）股份有限公司 结合人cd38的抗体、其制备方法和用途
KR20230066404A (ko) 2020-09-10 2023-05-15 카시 파마슈티컬스, 인코포레이티드 혈액 스크리닝 방법
CN116406291A (zh) 2020-10-05 2023-07-07 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022097047A1 (en) * 2020-11-04 2022-05-12 Medimmune, Llc Treatment methods using anti-bcma antibody-drug conjugates
WO2022112469A1 (en) 2020-11-27 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring of toxic epidermal necrolysis
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
EP4337763A1 (en) 2021-05-10 2024-03-20 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
AR125851A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas
US20220378829A1 (en) 2021-05-12 2022-12-01 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating solid tumors
US20250304915A1 (en) 2021-05-25 2025-10-02 Institut Curie Myeloid Cells Overexpressing BCL2
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
EP4376869A1 (en) 2021-07-28 2024-06-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023056361A1 (en) 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
MX2024005392A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
AU2022380155A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
JP2024546152A (ja) * 2021-12-16 2024-12-17 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
AU2023221861A1 (en) 2022-02-18 2024-09-05 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
WO2023178323A1 (en) * 2022-03-18 2023-09-21 Henry Ford Health System Therapeutic inhibition of cd38 to treat hidradenitis suppurativa
EP4499677A1 (en) 2022-03-31 2025-02-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
IL315770A (en) 2022-04-01 2024-11-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
JP2025517650A (ja) 2022-05-11 2025-06-10 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20250040020A (ko) 2022-07-19 2025-03-21 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
EP4583876A1 (en) 2022-09-08 2025-07-16 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
IL320230A (en) 2022-10-14 2025-06-01 Janssen Pharmaceutica Nv A method for detecting antibody-dependent cellular phagocytosis
KR20250093336A (ko) 2022-10-25 2025-06-24 제넨테크, 인크. 다발성 골수종에 대한 치료 및 진단 방법
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體及其用途
KR20250097946A (ko) 2022-11-02 2025-06-30 얀센 바이오테크 인코포레이티드 암을 치료하는 방법
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
JP2026504491A (ja) 2023-02-03 2026-02-05 ツェー３エス２ ゲーエムベーハー 操作された免疫細胞の非ウイルス的製造のための方法
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20260036568A (ko) * 2023-07-10 2026-03-17 카스젠 라이프 사이언스 씨오., 엘티디. 세포 면역 요법용 조성물, 및 방법
WO2025027003A1 (en) * 2023-07-31 2025-02-06 Sanofi Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025157744A (ja) * 2024-04-03 2025-10-16 株式会社三洋物産 遊技機
JP2025157743A (ja) * 2024-04-03 2025-10-16 株式会社三洋物産 遊技機
WO2025229160A1 (en) 2024-05-01 2025-11-06 Commit Biologics Aps Engineered proteins that engage complement factor and a protein antigen, methods, and uses thereof
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025261432A1 (en) * 2024-06-21 2025-12-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-cdcp1 antibodies and uses thereof
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy

Family Cites Families (331)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6168A (en) 1849-03-13 Horizontal spark-arrester
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US54A (en) 1836-10-15 Art of managing and supplying fie-e for generating steam in locomotive
US576A (en) 1838-01-20 Ftjbnace of stoves fob bubning anthracite
US5719A (en) 1848-08-22 Ditching-machine
US5672A (en) 1848-07-18 Mark wilder
US510A (en) 1837-12-07 soeel
US5922A (en) 1848-11-14 Improvement in hillside-plows
US941A (en) 1838-09-22 Machine for sawing shingles and staves
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5834185A (en) 1986-10-28 1998-11-10 Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
EP0404835A4 (en) 1988-03-18 1991-05-08 Us Health Novel recombinant vaccinia virus expression vectors and method of selecting same
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
JP3203599B2 (ja) 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JP2507895B2 (ja) 1989-12-19 1996-06-19 工業技術院長 リボザイムの新規合成系
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2151463T5 (es) 1989-12-22 2012-10-29 Merck Serono Sa Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5723289A (en) 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5869641A (en) 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5846713A (en) 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5780228A (en) 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
JPH06504186A (ja) 1990-07-13 1994-05-19 ザ ジェネラル ホスピタル コーポレイション Ｃｄ５３細胞表面抗原とその使用
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
GB9023352D0 (en) 1990-10-26 1990-12-05 Lynxvale Ltd Vaccinia vectors,vaccinia genes and expression products thereof
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5683874A (en) 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
US6028186A (en) 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
CA2112473A1 (en) 1991-07-05 1993-01-21 Patricia A. Bacha Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
HUT67943A (en) 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
ATE208374T1 (de) 1992-02-18 2001-11-15 Otsuka Kagaku Kk Beta-laktam und cepham verbindungen und ihre herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5972699A (en) 1992-05-14 1999-10-26 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting herpes simplex virus replication
US6017756A (en) 1992-05-14 2000-01-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting hepatitis B virus replication
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5646020A (en) 1992-05-14 1997-07-08 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes for preferred targets
US5989906A (en) 1992-05-14 1999-11-23 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
AU672018B2 (en) 1992-07-02 1996-09-19 Sankyo Company Limited Looped, hairpin ribozyme
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5646042A (en) 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5891684A (en) 1992-10-15 1999-04-06 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5811300A (en) 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5612215A (en) 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
AU6088094A (en) 1993-01-15 1994-08-15 General Hospital Corporation, The Rna assays using rna binary probes and ribozyme ligase
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
AU688321B2 (en) 1993-04-21 1998-03-12 Institut Pasteur Biocompatible implant for the expression and secretion in vivo of a therapeutic compound
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
CA2164288A1 (en) 1993-06-04 1994-12-22 Barbara Ensoli Method for treating kaposi's sarcoma with antisense oligonucleotides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
ATE227342T1 (de) 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
US5861288A (en) 1993-10-18 1999-01-19 Ribozyme Pharmaceuticals, Inc. Catalytic DNA
US5616466A (en) 1993-11-05 1997-04-01 Cantor; Glenn H. Ribozyme-mediated inhibition of bovine leukemia virus
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5712384A (en) 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
US5580766A (en) 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
US5639647A (en) 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
US5595873A (en) 1994-05-13 1997-01-21 The Scripps Research Institute T. thermophila group I introns that cleave amide bonds
US5580967A (en) 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
US5683902A (en) 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5650316A (en) 1994-06-06 1997-07-22 Research Development Foundation Uses of triplex forming oligonucleotides for the treatment of human diseases
US5998193A (en) 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US5633133A (en) 1994-07-14 1997-05-27 Long; David M. Ligation with hammerhead ribozymes
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5688670A (en) 1994-09-01 1997-11-18 The General Hospital Corporation Self-modifying RNA molecules and methods of making
AU7954794A (en) 1994-09-12 1996-03-29 City Of Hope Modulation of drug radiation resistant genes
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
JPH08113591A (ja) 1994-10-14 1996-05-07 Taiho Yakuhin Kogyo Kk オリゴヌクレオチド及びこれを有効成分とする制癌剤
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5683873A (en) 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US5770715A (en) 1995-03-22 1998-06-23 Toagosei Co., Ltd. Hammerhead-like nucleic acid analogues and their synthesis
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1996033279A2 (en) 1995-04-21 1996-10-24 Abbott Laboratories Repertoire cloning process, products derived therefrom and uses for said products
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5646031A (en) 1995-05-16 1997-07-08 Northern Illinois University SArMV and sCYMVI hairpin ribozymes
US6020130A (en) 1995-06-07 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands that bind to and inhibit DNA polymerases
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5693773A (en) 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5910408A (en) 1995-06-07 1999-06-08 The General Hospital Corporation Catalytic DNA having ligase activity
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
AU6691496A (en) 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
NO953680D0 (no) 1995-09-18 1995-09-18 Hans Prydz Cellesyklusenzymer
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO1997018312A1 (en) 1995-11-14 1997-05-22 Vimrx Holdings, Ltd. Chimeric oligomers having an rna-cleavage activity
CZ154898A3 (cs) 1995-11-21 1998-09-16 Icn Pharmaceuticals, Inc. Oligonukleotidy pro inhibici růstu nádorů zprostředkovaných IL-8 a receptorem IL-8
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
CN1215994A (zh) 1996-02-15 1999-05-05 国家健康学会 对治疗rsv感染有效的rna酶l激活剂和反义寡核苷酸
US5877162A (en) 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
EP0954340B1 (en) 1996-05-03 2007-06-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
MY150893A (en) 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1998016245A1 (fr) 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Procede de determination d'un auto-anticorps
DK0932417T3 (da) 1996-10-17 2003-04-14 Immunomedics Inc Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5874566A (en) 1996-10-25 1999-02-23 Hisamitsu Pharmaceutical Co. Inc. Il-15 triplex oligonucleotides
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3835827B2 (ja) 1997-05-02 2006-10-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
EP0996735B1 (en) 1997-06-09 2003-12-10 Genvec, Inc. Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU7976198A (en) 1997-06-19 1999-01-04 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes with extended cleavage rule
US6300483B1 (en) 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
JP2001517455A (ja) 1997-09-23 2001-10-09 ジェンベク、インコーポレイティッド 真核生物ウイルスベクター構築用プラスミド
CA2248762A1 (en) 1997-10-22 1999-04-22 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of tnf-.alpha.
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
IL139040A0 (en) 1998-04-22 2001-11-25 Genvec Inc Efficient purification of adenovirus
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US5965358A (en) 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
SI1108035T1 (sl) 1998-09-04 2007-12-31 Sanofi Pasteur Ltd Zdravljenje raka materničnega vratu
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US6242259B1 (en) 1998-12-31 2001-06-05 Chiron Corporation Compositions and methods for packing of alphavirus vectors
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20050037969A1 (en) 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
WO2001081609A2 (en) 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
US6168941B1 (en) 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
US20030170871A1 (en) 2000-04-25 2003-09-11 Chiron Corporation Alphavirus-based vectors for persistent infection
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
CA2424643A1 (en) 2000-10-17 2002-04-25 Trudeau Institute, Inc. Cd38 modulated chemotaxis
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20030157030A1 (en) 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002360394A1 (en) 2001-11-16 2003-06-10 University Of Massachusetts Facilitation of rna interference
US20030167490A1 (en) 2001-11-26 2003-09-04 Hunter Craig P. Gene silencing by systemic RNA interference
WO2003048185A2 (en) 2001-11-30 2003-06-12 Genvec, Inc. Angiopioetin related factors
US20040009498A1 (en) 2002-01-14 2004-01-15 Diversa Corporation Chimeric antigen binding molecules and methods for making and using them
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20040019915A1 (en) * 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
US7399586B2 (en) 2002-05-23 2008-07-15 Ceptyr, Inc. Modulation of biological signal transduction by RNA interference
CA2486658C (en) 2002-05-31 2014-07-29 The Regents Of The University Of California Method for efficient rna interference in mammalian cells
GB2406169B (en) 2002-06-12 2006-11-01 Ambion Inc Methods and compositions relating to labeled rna molecules that reduce gene expression
EP1393720A1 (en) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CA2542840A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
KR101128777B1 (ko) * 2003-11-04 2012-04-13 조마 테크놀로지 리미티드 다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
US20050266008A1 (en) 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
US20060019303A1 (en) 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
PH12017500442B1 (en) * 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
CN107406506A (zh) * 2014-12-04 2017-11-28 詹森生物科技公司 用于治疗急性髓系白血病的抗cd38抗体
IL256242B2 (en) * 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
EA037548B1 (ru) * 2015-06-24 2021-04-12 Янссен Байотек, Инк. Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38

Also Published As

Publication number Publication date
US20200283542A1 (en) 2020-09-10
LUC00053I1 (sr) 2017-12-07
SG10201912554TA (en) 2020-02-27
IL231919B (en) 2020-02-27
LUC00053I2 (fr) 2018-02-21
JP6777779B2 (ja) 2020-10-28
AU2006226733B2 (en) 2012-12-06
US20240132620A1 (en) 2024-04-25
IL185751A (en) 2014-04-30
EP2551282A3 (en) 2013-02-13
IL284991A (en) 2021-08-31
EA200702053A1 (ru) 2008-02-28
EP2535355B1 (en) 2019-01-02
SI2567976T1 (sl) 2017-11-30
JP6494053B2 (ja) 2019-04-03
EA015584B1 (ru) 2011-10-31
JP2012070737A (ja) 2012-04-12
LTPA2017040I1 (lt) 2018-01-10
CY1118369T1 (el) 2017-06-28
NZ561883A (en) 2010-11-26
HRP20191768T1 (hr) 2019-12-27
AU2006226733C9 (en) 2019-03-14
IL231919A0 (en) 2014-05-28
LTC2567976I2 (lt) 2019-06-25
DK2567976T3 (en) 2017-10-23
CN112480257A (zh) 2021-03-12
AU2006226733A8 (en) 2013-01-10
JP2019037228A (ja) 2019-03-14
AU2006226733A1 (en) 2006-09-28
JP2008533977A (ja) 2008-08-28
EP2535355A2 (en) 2012-12-19
JP2020141689A (ja) 2020-09-10
US9187565B2 (en) 2015-11-17
NZ586780A (en) 2012-02-24
EA037929B1 (ru) 2021-06-08
NL300915I1 (sr) 2017-12-06
HK1107826A1 (zh) 2008-04-18
IL296666A (en) 2022-11-01
JP2021121195A (ja) 2021-08-26
JP2019146560A (ja) 2019-09-05
EP3312196B1 (en) 2019-07-17
EP1866338B1 (en) 2016-09-21
CY1119454T1 (el) 2018-03-07
CN101218256B (zh) 2017-04-19
FR18C1003I2 (fr) 2020-02-28
CY2017044I2 (el) 2018-09-05
US20160130362A1 (en) 2016-05-12
LUC00053I9 (fr) 2018-07-03
JP2023017781A (ja) 2023-02-07
MX2007011064A (es) 2008-02-19
AU2006226733C1 (en) 2019-02-14
CA2602375C (en) 2018-07-24
CN101218256A (zh) 2008-07-09
EP2567976A3 (en) 2013-04-03
ES2716874T3 (es) 2019-06-17
EP2567976A2 (en) 2013-03-13
AU2006226733B8 (en) 2013-01-10
BRPI0608927B1 (pt) 2021-11-23
KR20070116137A (ko) 2007-12-06
NL300915I2 (nl) 2020-10-26
ZA200709003B (en) 2009-05-27
JP6578423B2 (ja) 2019-09-18
ME03528B (me) 2020-04-20
JP2024059959A (ja) 2024-05-01
IL185751A0 (en) 2008-01-06
JP2018080171A (ja) 2018-05-24
HRP20161766T1 (hr) 2017-02-24
IL316252A (en) 2024-12-01
CN107033243A (zh) 2017-08-11
US7829673B2 (en) 2010-11-09
JP5225069B2 (ja) 2013-07-03
KR101433381B1 (ko) 2014-10-02
WO2006099875A1 (en) 2006-09-28
US20240228662A9 (en) 2024-07-11
CN107033243B (zh) 2020-12-15
PL2567976T3 (pl) 2018-01-31
EP2567976B1 (en) 2017-07-19
JP2014110800A (ja) 2014-06-19
IL322052A (en) 2025-09-01
EP3312196A1 (en) 2018-04-25
CA2602375A1 (en) 2006-09-28
EP2551282A2 (en) 2013-01-30
JP2020028294A (ja) 2020-02-27
US20090148449A1 (en) 2009-06-11
EP1866338A1 (en) 2007-12-19
JP6952088B2 (ja) 2021-10-20
CY2017044I1 (el) 2018-09-05
JP5971918B2 (ja) 2016-08-17
WO2006099875A8 (en) 2007-05-03
IL272273A (en) 2020-02-27
EP3153525A1 (en) 2017-04-12
EA201100694A1 (ru) 2012-02-28
US20110099647A1 (en) 2011-04-28
JP2016169226A (ja) 2016-09-23
EP2535355A3 (en) 2013-02-20
CN119119271A (zh) 2024-12-13
IL304150A (en) 2023-09-01
BRPI0608927A2 (pt) 2010-11-09

Similar Documents

Publication Publication Date Title
RS59399B1 (sr) Antitela protiv cd38 za lečenje multiplog mijeloma
KR101397352B1 (ko) 4-치환된 페녹시페닐아세트산 유도체
AU684887B2 (en) Isoxazoline compounds as inhibitors of TNF release
WO2003084930A1 (fr) Derives de diphenylpyridine, leur preparation, les compositions pharmaceutiques en contenant
CA2554855A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine- carboxylates, leur preparation et leur application en tant qu&#39;inhibiteurs de l&#39;enzyme faah
JP2008530179A (ja) カンナビノイドｃｂ２受容体モジュレーターとしての１ｈ−イミダゾール誘導体
JP2002501056A (ja) マトリクス金属プロテイナーゼ阻害薬としての２，３，４，５−テトラヒドロ−１ｈ−［１，４］−ベンゾジアゼピン−３−ヒドロキサム酸
CN101087754B (zh) 环己烷衍生物
CN110483425B (zh) 一种酰基硫脲类化合物及其制备方法与抗甲型流感病毒的应用
WO2019167085A1 (en) Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
JP2006512302A (ja) ＡＣＡＴ阻害活性を有するα−フェニルアセトアニリド誘導体およびその治療的適用
WO1998052919A1 (en) Phthalimide derivatives and pharmaceutical containing said derivatives
KR20080089413A (ko) 카나비노이드 ｃｂ1 수용체 조절자로서의4,5-디하이드로-(1ｈ)-피라졸 유도체
EP2027081B1 (en) Therapeutic prostaglandin compounds for the treatment of glaucoma
KR100362789B1 (ko) 5-리폭시게네이즈 저해제를 제조하기 위한 방법 및 중간체
EP1675833B1 (en) 1h-imidazole derivatives as cannabinoid receptor modulators
US8937184B2 (en) 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
US6005118A (en) Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
US7985767B2 (en) Therapeutic amides
AU2005256109A8 (en) Process for the preparation of anastrozole
FR2792635A1 (fr) Derives de cyclobutene-3,4-dione leur preparation et leur application en therapeutique
CN101107233A (zh) 作为大麻素cb2受体调节剂的1h－咪唑衍生物
US5710180A (en) Phenethylamine compounds
CN101076520B (zh) 具有cb1-拮抗活性的咪唑啉衍生物
US8198318B2 (en) Therapeutic amides